Prospective study on human fecal carriage of Enterobacteriaceae possessing mcr-1 and mcr-2 genes in a regional hospital in Hong Kong

Table 1 Subject details and antibiotic susceptibilities of the 14 mcr-1-positive E. coli strains

Subject	Age/Year	Subject type^a	ESBL^b producer?	Carbapenem susceptible?	PB MIC^c (μg/mL)	PE MIC^d (μg/mL)	PE MIC^e (μg/mL)	Non-susceptible antibiotics^g (based on CLSI guidelines)
1^f	45	OP	No	Yes	8	4	8	AM^R, CF^I, SXT^R
2	54	HA	No	Yes	8	2	8	SXT^R
3	42	IP	No	Yes	8	4	8	CF^I, MI^I, SXT^R
4	54	HA	No	Yes	12	4	8	AM^R, AMC^I, AN^I, MI^R, SXT^R
5	2	IP	No	Yes	4	4	4	AM^R, AMC^R, AN^R, CF^R, CIP^R, CN^R, CXM^R, LEV^I, SXT^I, TIM^R, TOB^R, TZP^R
6	45	HA	No	Yes	8	4	8	AM^R, AMC^I, CIP^R, CN^R, CXM^I, LEV^R, SXT^R, TIM^I, TOB^R
7	43	HA	No	Yes	8	4	4	AM^R, AMC^I, CF^R, CIP^I, CXM^I, LEV^I, MI^I, SXT^R, TIM^I, TZP^R
8	31	HA	No	Yes	12	4	> 16	All susceptible
9	52	HA	No	Yes	4	2	4	CF^I, CXM^I
10^f	1	IP	No	Yes	6	4	8	AM^R, AN^I, CF^R, CXM^I, MI^I, TOB^I
11	58	HA	No	Yes	8	4	8	AM^R, SXT^R
12	7	OP	Yes	Yes	12	4	4	AM^R, AMC^R, CAZ^R, CF^R, CTX^R, CXM^R, FEP^R, SXT^R
13	49	HA	Yes	Yes	8	4	4	AM^R, AMC^R, AN^I, CAZ^R, CF^R, CIP^R, CN^R, CTX^R, CXM^R, FEP^R, LEV^I, SXT^R, TOB^R
14	55	HA	No	Yes	6	2	2	AM^R, CF^R, CIP^I, CXM^I, MI^I, SXT^R

^aOP outpatients, HA clients coming for health assessment, IP inpatients
^bESBL, extended-spectrum β-lactamase
^cPB MIC, Polymyxin B minimum inhibitory concentration by Etest
^dPE MIC, Polymyxin E (colistin) minimum inhibitory concentration by broth microdilution (SensiTest Colistin)
^ePE MIC, Polymyxin E (colistin) minimum inhibitory concentration by Vitek® 2 AST N-338
^fThe subjects had received antibiotic treatment other than colistin prior to fecal specimen collection
^gI intermediate, R resistant, AM ampicillin, AMC amoxicillin-clavulanate, AN amikacin, CAZ ceftazidime, CF cephalothin, CIP ciprofloxacin, CN gentamicin, CTX cefotaxime, CXM cefuroxime, FEP cefepime, LEV levofloxacin, MI minocycline, SXT trimethoprim/sulfamethoxazole, TIM ticarcillin-clavulanate, TOB tobramycin, TZP piperacillin-tazobactam

ISSN: 1471-2334